Company research
CURIS INC
CIK 1108205Updated Sep 24, 2026
SecurityCRIS · NASDAQ · equity
CRIS price & chart
Loading TradingView…
NASDAQ:CRIS on TradingView ↗About the company
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
In the news
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Curis, Inc. Oct 03, 2025, 16:00 ET Share this article Share to X Share this article Share to X LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the dev ↗
Recent filings
10-Q filing
424B4 filing
EFFECT filing
S-1 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Show 5 more recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
8-K/A filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03
Submission of Matters to a Vote of Security Holders
Items 5.07
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 19,966,000Source | 41,265,000Source | 77,282,000Source | 108,848,000Source |
| Property, Plant and Equipment, NetUSD | 62,000Source | 231,000Source | 434,000Source | 689,000Source |
| GoodwillUSD | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,061,000Source | 19,997,000Source | 26,681,000Source | 19,658,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 3,349,000Source | 2,794,000Source | 2,975,000Source |
| Assets, CurrentUSD | 6,915,000Source | 26,385,000Source | 60,908,000Source | 92,119,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,854,000Source | 3,039,000Source | 1,780,000Source | 3,521,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,890,000Source | 3,163,000Source | 3,056,000Source | 4,401,000Source |
| Other Assets, NoncurrentUSD | 1,573,000Source | 1,960,000Source | 3,358,000Source | 2,022,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,504,000Source | 47,263,000Source | 57,612,000Source | 62,296,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 129,000Source | 85,000Source | 59,000Source | 966,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,247,381,000Source | -1,239,799,000Source | -1,196,410,000Source | -1,148,997,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 0Source | 229,000Source | -186,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,462,000Source | -5,998,000Source | 19,670,000Source | 46,552,000Source |
| Additional Paid in Capital, Common StockUSD | 1,252,714,000Source | 1,233,716,000Source | 1,215,792,000Source | 1,194,769,000Source |
| Liabilities and EquityUSD | 19,966,000Source | 41,265,000Source | 77,282,000Source | 108,848,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 14,076,000Source | 19,027,000Source | 13,517,000Source | 10,013,000Source |
| Operating Lease, Liability, CurrentUSD | 1,190,000Source | 1,336,000Source | 1,305,000Source | 1,141,000Source |
| Accounts Payable, CurrentUSD | 5,612,000Source | 3,024,000Source | 3,172,000Source | 3,193,000Source |
| Operating Lease, Liability, NoncurrentUSD | 428,000Source | 1,618,000Source | 1,489,000Source | 2,800,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,274,000Source | 7,111,000Source | 9,040,000Source | 5,679,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 5,100,000Source | 20,000,000Source | 56,300,000Source | 85,600,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 7,556,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,018,000Source | 5,927,000Source | 6,000,000Source | 6,752,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,032,000Source | 555,000Source | -181,000Source | -249,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -27,201,000Source | -39,563,000Source | -38,434,000Source | -54,337,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 2,500,000Source | 29,442,000Source | 37,786,000Source | 33,023,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 0Source | 416,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,765,000Source | 3,437,000Source | 7,580,000Source | 867,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -14,936,000Source | -6,684,000Source | 6,932,000Source | -20,447,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,605,000Source | 20,541,000Source | 27,225,000Source | 20,293,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,534,000Source | 461,000Source | 2,359,000Source | 4,112,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,018,000Source | 5,927,000Source | 6,000,000Source | 6,752,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 5,100,000Source | 20,000,000Source | 56,300,000Source | 85,600,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 27,189,000Source | — | — | — |
| General and Administrative ExpenseUSD | 14,046,000Source | 16,790,000Source | 18,647,000Source | 19,648,000Source |
| GoodwillUSD | 8,982,000Source | 8,982,000Source | 8,982,000Source | 8,982,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 316,000Source | 1,768,000Source | 2,938,000Source | 1,119,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | -229,000Source | 415,000Source | -77,000Source |
| Net Income (Loss) Attributable to ParentUSD | -7,582,000Source | -43,389,000Source | -47,413,000Source | -56,672,000Source |
| Nonoperating Income (Expense)USD | -1,869,000Source | 1,153,000Source | 919,000Source | -3,652,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source |
| Payments to Acquire InvestmentsUSD | 0Source | 18,098,000Source | 70,340,000Source | 62,000,000Source |
| Proceeds from Issuance of Common StockUSD | 15,352,000Source | 12,023,000Source | 14,117,000Source | 5,594,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 9,443,000Source | 10,908,000Source | 10,023,000Source | 10,162,000Source |
| Operating Income (Loss)USD | -5,713,000Source | -44,542,000Source | -48,332,000Source | -53,020,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,582,000Source | -43,389,000Source | -47,413,000Source | -56,672,000Source |
| Earnings Per Share, BasicUSD per share | -0.58Source | -6.88Source | -8.96Source | 0.61Source |
| Earnings Per Share, DilutedUSD per share | -0.58Source | -6.88Source | -8.96Source | 0.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 13,164,032Source | 6,306,284Source | 5,293,294Source | 93,392,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 13,164,032Source | 6,306,284Source | 5,293,294Source | 93,392,515Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 42,345,000Source | 55,450,000Source | 58,355,000Source | 63,182,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 169,000Source | 203,000Source | 255,000Source | 233,000Source |
| General and Administrative ExpenseUSD | 14,046,000Source | 16,790,000Source | 18,647,000Source | 19,648,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 316,000Source | 1,768,000Source | 2,938,000Source | 1,119,000Source |
| Nonoperating Income (Expense)USD | -1,869,000Source | 1,153,000Source | 919,000Source | -3,652,000Source |
Offerings
Registration 333-298203
- Gross proceeds
- 5600000.0
- Net proceeds
- 5236000.0
- Deal price
- 1.5
- Shares
- 3733333
- Offering price
- $1.50
- Ticker
- CRIS
Registration 333-289456
Filing attachments
ex41formofpre-fundedwarrant.htm · 8-K · 2025-03-28
EX-4.1 2 ex41formofpre-fundedwarrant.htm EX-4.1 Document EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES …
Read attachment ↗ex42-formofcommonstockwarr.htm · 8-K · 2025-03-28
EX-4.2 3 ex42-formofcommonstockwarr.htm EX-4.2 Document EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A…
Read attachment ↗